Why Edwards Lifesciences' Q3 Results Aren't Bad News
October 25, 2016 at 21:41 PM EDT
A recent FDA approval significantly expands the company's addressable patient population in aortic stenosis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.